Half Year 2025 Biocon Ltd Earnings Call Transcript
Key Points
- Biocon Ltd (BOM:532523) reported operating revenue growth of 4%, with an 8% increase on a like-for-like basis after adjustments.
- The biosimilars business showed healthy double-digit growth, with significant market share increases in the US for products like Ogivri and Fulphila.
- Successful refinancing of long-term debt by Biocon Biologics through a bond issue and a new syndicated loan facility on improved terms.
- Biosimilar revenue from operations grew 19% on an adjusted basis, reflecting strong underlying profitability.
- Biocon Biologics continues to expand its global footprint, achieving double-digit growth in the UK and Mediterranean regions.
- Overall performance was relatively muted due to continued pressures in the generic business and a marginal decline in Syngene's revenues.
- The generics business faced an 8% year-on-year revenue decline, impacted by demand and pricing challenges.
- Reported net loss for the quarter was INR16 crore, attributed to higher tax basis and geographical profit splits.
- US FDA inspections at two API facilities resulted in observations, requiring corrective actions and awaiting feedback.
- The company is facing challenges in ramping up market share in the Humira biosimilar market in the US.
Good evening, everyone. I am Saurabh Paliwal from Biocon's Investor Relations team, and I welcome you to the Biocon's earnings call for the second quarter of fiscal year '25. (Event Instructions) Please note that the chat box is disabled, but you can raise any technical concerns by sending us an e-mail to [email protected].
I would like to bring your attention that this conference call is being recorded. The recording will be available on our website within a day. And the transcript will be made available subsequently. To discuss this quarter's business performance and future outlook for the company, we have with us on the call, Group CEO, Mr. Peter Bains, Mr. Siddharth Mittal, CEO and MD of Biocon Limited; Mr. Shreehas Tambe, CEO and MD of Biocon Biologics Limited, along with other senior management colleagues across our business segments.
Before we begin, I would want to remind everyone about the safe harbor related to today's call. Comments made during the call may be forward-looking in nature, based on management's current
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
